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Summary 
 
- There is a need for physical standards (reference materials) to ensure both 
reproducibility and consistency in the production of somatic cell types from human 
pluripotent stem cell sources. 
- We outline the need for reference materials (RM) in relation to the unique properties 
and concerns surrounding hPSC-derived products and suggest in-house approaches to 
RM generation relevant to basic research, drug screening and therapeutic applications.  
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Abstract 
 
Human pluripotent stem cells (hPSCs) have an unparalleled potential as a source of 
somatic cells for drug screening, disease modelling and therapeutic application. Undefined 
variation and product variability following differentiation to the lineage or cell type of 
interest impede efficient translation and may obscure the evaluation of clinical safety and 
efficacy. Moreover, in the absence of a consistent population, data generated from in vitro 
studies may be unreliable and irreproducible. Efforts to devise approaches and tools that 
facilitate improved consistency of hPSC-derived products, both as development tools and 
therapeutics products, will aid translation. Standards exist in both written and physical 
forms; but because many unknown factors persist in the field, premature written standards 
may inhibit rather than promote innovation and translation. Here we are focused on the 
derivation of physical standards-RM. We outline the need for RM and assess approaches 
to in-house RMgeneration for hPSC-derived products, a critical tool for the analysis and 
control of product variation that can be applied by researchers and developers. We then 
explore potential routes for the generation of RM, which include both cellular and non-
cellular materials as well as novel methodologies that may provide valuable tools to 
measure and account for variation. Multiparametric techniques to identify ‘signatures’ for 
therapeutically relevant cell types, such as neurons and cardiomyocytes that can be 
derived from hPSCs, would be of significant utility, although physical RM will be required 
for clinical purposes.  
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Introduction 
 
Human pluripotent stem cell (hPSC) technologies have a unique potential to address the 
increasing burden of unmet clinical need for many intractable diseases. However, a grasp 
of the fundamental biology, which is necessary to ensure invariant and reproducible safe 
and effective cellular products from batch-to-batch and patient-to-patient, has eluded our 
reach. The field generally lacks standards that will enable scalable, automated 
manufacturing to build regulatory confidence and meet clinical needs.  
 
Written standards exist in a vast range of industries, enabling dialogue between 
stakeholders via a common set of ‘rules’ or ‘guidelines’. Typically developed through 
consensus that emerges through an incremental process of discussion and revision 
amongst experts, standards can establish specifications, set minimum requirements and 
provide a route by which valid comparisons can be made. Standards can also serve to 
protect the integrity of manufacturers, stimulate consumer confidence and facilitate the 
uptake of new technologies into the market [1-3]. Physical standards are materials used 
for specific comparative purposes to validate and provide a benchmark for assessments.  
 
Outlining the need for routes to generating both developer-specific and, where 
appropriate, consensus physical (material) standards for stem cell translation has value for 
two primary reasons. Firstly, physical standards will support and enable improved 
reproducibility and product consistency in research. Currently the field, and biomedical 
research in general, suffers from issues of irreproducibility [4, 5], which impedes progress 
and effective collaboration and could damage the public perception of stem cell research. 
Secondly, there are commercial and translational benefits of incorporating standardization 
principles early in R&D, by building a base for quality assessment to prevent undue delays 
throughout clinical trials because of deficiencies in necessary tools and data to meet 
regulatory requirements. Therefore, approaches for the derivation of standards, and 
especially, physical (material) standards may benefit early-stage researchers conducting 
pre-clinical phase investigation, as well as those engaged further along the translation 
pathway. However, it is vital to strike the proper balance here to ensure that the benefits of 
standardization are not achieved at the expense of hindering innovation. Here we are not 
trying to identify the preferred PSC line to generate clinical products, nor a specification for 
the optimal cell type.  Instead we are focused on the need and possible mechanisms by 
which physical standards-RM, can be produced to analyse and therefore facilitate the 
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consistent and reproducible generation of products from hPSCs. As consensus 
(international) RM may have limited application and will be more challenging to achieve, 
we focus on in-house developer-specific RMthat can be generated by research 
laboratories and companies alike that are engaged in pre-clinical research, and that can 
be applied in clinical trials and beyond to meet with regulatory expectations. These 
principles and approaches also have application in drug screening and toxicology studies 
that utilize PSC-derived somatic cells with underlying expectations for reproducibility and 
consistency. 
 
 
The clinical potential of PSC-derived products 
 
The utility of hPSCs in disease modelling is beginning to be demonstrated and some of 
these models are now finding application as drug screening tools (reviewed in [6-8]). 
However, it is the application of PSCs as a cell source for therapeutic intervention that still 
garners the greatest enthusiasm within a healthcare context. To date, ESC-derived 
products have entered a limited number of clinical trials, pioneered by Geron Corporation 
(Menlo Park, CA, USA, assets now owned by Asterias Biotherapeutics) and more recently 
Advanced Cell Technology (ACT) Incorporated (Santa Monica, CA, USA), with a 
Pfizer/UCL trial scheduled to begin in 2014 [9, 10]. Although Geron did not complete its 
trial of ESC-derived oligodendrocyte precursors for acute spinal cord injury due to internal 
competing fund allocations, it pioneered a regulatory path and demonstrated the data 
requirement for testing PSC-derived products in humans [10]. This exercise proved 
educational not only for the private sector but also for the regulators themselves, who until 
that time had no experience evaluating the safety of hPSC-derived products in actual 
patients.  
 
Standards for hPSCs in their undifferentiated state are important for cell banking, both to 
demonstrate comparability and to show that cell lines are stable over time [11, 12]. A 
number of engaging perspectives on standards for hPSCs can be found [11, 13-15]. 
However, as hPSCs in their undifferentiated state will not be the final product delivered to 
research subjects or patients, standards should extend to validating early-stage 
translational research, as well as the manufacture and scale-up process by which large 
numbers of somatic cells are derived from hPSCs. As with any cell therapy, due to the 
unique nature of each product, written standards have limited utility for hPSC-derived 
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products. Instead material standards, generated on a case-by-case basis will be required 
to validate process, method and product consistency. While such material standards will 
be the responsibility of the developer and will vary in accordance with the particular 
developer’s technology, product and target indication, a clearer understanding of the need, 
requirements and potential approaches by which these materials standards could be 
produced will benefit academic researchers and industry alike.  
 
The challenges of hPSC translation 
 
The application of hPSC-derived products in a clinical setting is challenged by numerous 
inherent and unique barriers to translation, including scalability and manufacturability, as 
well as a variety of regulatory challenges (see Box.1 for an overview of challenges to the 
translation of hPSC-derived products).  
 
hPSCs are highly reactive to their external environment. They may undergo significant 
changes in response to different culture conditions, to extended time in culture, and 
following cryopreservation [16-18]. Stability is also a key issue, both genetic stability and 
physiological stability of hPSC-derived products.  In comparison to cells harvested from 
adult donors, hPSC-derived populations may have an increased propensity for continued 
proliferation, differentiation, and/or maturation. This was exemplified by the increased 
frequency of cyst formation from the ESC-derived oligodendrocyte precursor cell 
population in Geron’s pre-clinical animal studies, which resulted in the FDA placing the trial 
on hold. This issue was ultimately resolved by an additional level of cell selection [19]. 
Furthermore, hPSCs and their differentiated progeny have been demonstrated to be highly 
heterogeneous at the population level, with differentiation protocols asynchronously 
generating a variety of cell types [20]. Researchers are focusing on the generation of 
homogeneous differentiated populations from hPSCs that would be amenable to clinical 
demands. However, it has been argued that mixed populations might be preferable to a 
single cell type in some cases, if survival or efficacy of administered cells is enhanced by 
the presence of interacting cell types. It will be more challenging to characterize and 
control the consistency and quality of mixed populations, acknowledging that the level of 
heterogeneity in cell products will always exceed that of traditional small molecules.  
These inherent characteristics and current methodologies all create significant challenges 
for the development of RM for hPSC-derived products.  
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Standards and reference materials 
 
Standards fall into two main categories, written and physical (material), which must be 
clearly distinguished (Figure 1).  Written standards include codes of practice, standard 
operating procedures (SOPs), agreed terminology, guidelines and pharmacopoeia 
methods. Pharmacopoeia, particularly relevant to this discussion, are a series of 
monographs and general chapters documentation for active substances that outline the 
minimum requirements, describing identity, permissible levels of impurities in addition to 
appropriate methods to define purity and potency with accompanying expected ranges 
(USP, 2011). Pharmacopoeia may require the use of consensus physical (material) 
standards which currently only exist for small molecules and a limited number of biologics. 
The single example of a cell therapy monograph is currently being developed by the U.S 
Pharmacopoeia Convention (USP) for sipleucel-T (Provenge) (Dendreon, Seattle, WA, 
USA), a T cell therapy for advanced prostate cancer that has been authorized by the FDA, 
although approval of the monograph may encounter challenges and application may be 
limited (USP, 2013). There are a variety of local or regional organisations concerned with 
the publication of pharmacopoeia and/or production of physical reference standards (see 
Table 1). In addition, organizations such as the World Health Organisation (WHO), and the 
Joint Committee for Traceability in Laboratory Medicine (JCTLM)- the latter in the context 
of laboratory medicine and in vitro diagnostics, that lead and co-ordinate in the 
establishment of higher order international RM [21]. 
 
Box 1. Challenges to the translation of hPSC-derived 
products. 
- Phenotypic and genetic instability 
- Capacity to generate adult phenotypes 
- Cost of cell culture processes 
- IP protection clarity 
- Differentiation efficiencies and time scales 
- Tumorigenicity risks 
- Immunological considerations 
- Paucity regulatory and sponsor familiarity 
- Limited positive cell therapy outcomes to date 
- Each product must be considered by regulatory 
authorities on a case-by-case basis 
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RM are highly characterized physical materials used with analytical methods for a specific 
comparison purpose, and are a regulatory expectation globally [22-25]. Physical (material) 
standards can be sub-segmented into certified (consensus) and in-house (developer-
specific) materials (Figure 1). While certified RM are available for many biological 
substances, they have not yet been produced for cell therapies. The NIBSC has produced 
a RM of untouched (enrichment using negative selection techniques to prevent activation) 
CD4+ cell certified RM, intended for use in clinical diagnostics. This standard comprises 
fixed peripheral blood mononucleated cells (PBMCs) pre-labelled with a CD4 antibody 
conjugated to FITC (NIBSC, SS-222), this approach may have some relevance for cell 
therapies, as discussed below [26]. Certified (consensus) RM may have application when 
applied to specific characterization methodologies but are highly unlikely to have broad 
application, especially when considering the need for case-by-case development of cell 
therapies such as hPSC-derived products. Therefore, we focus here exclusively on in-
house (developer-specific) RM. There are two main categories of in-house, developer-
specific RM, ‘product’ and ‘method’ (Figure 1).  
 
Potential approaches to developing reference materials for hPSC-derived products 
 
The aim of this discussion is to support the development of approaches and assays that 
facilitate consistency and comparability in the production of differentiated cell types, such 
as cardiomyocytes, neurons and T cells from hPSCs, or ‘hPSC-derived products’. Batch-
to-batch variation, if not assessed and controlled, will affect the quality of clinical hPSC-
derived products. Moreover, approaches that enable the consistent production of 
differentiated cells will also be of significant benefit to drug and toxicity screening. There 
are numerous potential causes of variation in the production of somatic cells from hPSCs. 
‘Products’, such as cardiomyocytes, are generated from hPSCs by a highly dynamic 
differentiation process that may utilize a variety of methodologies [27], typically occurring 
via a number of stages. Even when considering the production of one specific product, 
from one hPSC line, using a single methodology, it is inevitable that the final product will 
demonstrate variability between individual batches. This variability will arise in the form of 
variable levels of heterogeneity and ‘purity’ of cell types, as well as inconsistencies in the 
differentiation and/or maturation stage of the product. Additionally, both genomic and 
phenotypic stability may demonstrate variation. Here we detail approaches to RM 
generation that may mitigate current inconsistency and irreproducibility concerns.  
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An overview of the possible approaches to establish RM for hPSC-derived products 
identifies two main categories: those that use living, cellular RM, either as product or 
method RM, and those involving non-living, non-cellular materials such as beads, DNA or 
RNA samples as method RM (Table 2). 
 
 
Product RM approaches 
 
‘Product’ RM should be representative of the product and are used to validate 
comparability assessments throughout the product’s lifecycle including process change 
and optimisation as well as to detect process drift (Figure 2i).  
 
The typical approach, which is common practice in the pharmaceutical industry, is to 
generate primary and secondary RM that are samples of the product batch generated for 
pre-clinical and then pivotal studies. Secondary RM are the ‘working’ samples used as a 
comparator in the relevant tests. Once samples are depleted, the secondary RM is 
generated from another batch and, through rigorous characterization, determined to be 
sufficiently comparable to the primary RM via a direct comparison. Ideally there would be a 
sufficient quantity of primary RM to last for the lifecycle of the product (over 10 years) 
however, and as discussed below, there may be limitations that preclude this period of 
coverage.  
 
A second potential methodology to product RM generation involves a ‘pooling’ approach, 
in which cells from a number of different batches are pooled. If RM are generated using a 
pooling approach then differences due to heterogeneity within the product are averaged 
out, providing a broad-ranging background against which measurements can be 
assessed. This may be beneficial in a number of circumstances.  
 
In a limited number of cases biologically equivalent cellular populations may be suitable 
product RM. For example if CD4+ T lymphocytes are derived from hPSC lines then CD4+ T 
lymphocytes harvested from healthy donors may be suitable as a product RM, or 
potentially as a method RM for a limited number of assays. This approach may only be 
appropriate for a limited number of cell types that can be obtained from healthy donors 
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without causing a detrimental effect. While this approach may have potential utility, it must 
be acknowledged that heterogeneity in the ‘biologically equivalent’ RM would need to be 
analysed and accounted for.  
 
The main considerations of whether these approaches may be suitable, in addition to the 
critical criteria of relevance in accordance with the product, are those of stability, feasibility 
and cost (Figure 3). Stability will need to be monitored over time and stability profiles 
determined so that new RM can be prepared before expiry. As batch sizes for hPSC-
derived products are expected to be smaller than is typically seen with small molecules, 
and even biologics, the amount of product that can be stored as RM will also be limited. 
The practicalities of RM quantity requirements will vary and will need to be mapped out 
and planned for by developers. An additional challenge for approaches that rely on cellular 
RM is that cell banks of differentiated products will need to be cryopreserved which will 
impact on viability but also potentially functional parameters. This becomes an issue if the 
product is to be used ‘fresh’ but is less of a concern if the product will be cryopreserved as 
part of the production process.  
 
Method RM approaches 
 
‘Method’ RM are used to qualify, validate and define acceptance criteria for specific 
assays, to calibrate methods and equipment, and to identify method drift over time (Figure 
2ii).  
 
Cell lines may be valuable method RM in some settings. An example of such an approach 
is the use of embryonal carcinoma line 2102Ep, which has a good stability profile in 
culture. This cell line demonstrated utility in flow cytometry assays for the characterization 
of a range of hESCs by the International Stem Cell Initiative (ISCI) [28], in spite of a 
number of reported biological differences between hESCs and the EC line [15, 29]. This 
approach may also be relevant for a number of differentiated cell types, if an appropriate 
cell line is available or can be produced. Immortalization of primary cells to generate stable 
cell lines impacts upon signalling pathways and some phenotypic characteristics; therefore 
the suitability of cell lines as method RM will depend on the application. It should also be 
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acknowledged that the standardization, characterization and qualification of cell lines as 
method RM would take a considerable amount of work-up and validation. 
 
Non-cellular/(nonviable) method RM could include fixed cells, beads, DNA/RNA samples 
and reference cytokines. Fixed cells, most suitably from a product sample, can be used as 
a RM for assays that compare cell surface marker expression, such as the clinical 
application of the NIBSC CD4+ T cell sample for HIV testing, as well as applications to 
assess heterogeneity/composition criteria [26]. However, the process of fixation changes 
the properties of the cell, which may negate use as a method RM when compared to the 
non-fixed product in some flow cytometry-based assays. Bead-based approaches have 
been used routinely for flow cytometry purposes, to both calibrate and establish baseline 
readings for cytometers and to apply compensation settings. However, bead-based 
approaches also encounter stability issues and would most likely need to be used in 
conjunction with a cellular method RM.  
 
RM for molecular biology assays should be easily achievable as DNA, and RNA samples 
in the appropriate conditions, demonstrate good stability profiles, are easily stored and can 
be generated in large quantities relative to the amount of material required for any given 
assay. In most cases method RM for molecular biology assays would be produced from a 
sample of the product batch. One issue to be considered is selection of suitable positive 
controls in assays such as RT-PCR. (Semi)-quantitative measurements of gene 
expression are typically made in relation to the expression of ‘housekeeping genes’. 
However, a number of studies have identified changes in the expression levels of these 
presumably stable genes in concordance with the differentiation status of hPSCs and 
other stem cell types and, therefore, are an unsuitable baseline for these assays [30, 31]. 
Similarly, while microarray-based assays detect the relative levels of all transcripts in the 
genome, they do not identify alternatively spliced transcripts that may be critical for cellular 
function.  RNA sequencing (RNAseq) is growing in popularity and has the potential for 
identifying splice variants and absolute amounts of transcripts.  A challenge for an RNAseq 
approach, however, is the large variation in results from different sequencing labs, a 
problem that must be solved by a normalization method before sequencing-based assays 
can be reliable- another example of the need for physical reference materials to enable 
comparability testing. Written standards that identify a consensus minimum requirement 
for qRT-PCR and microarray assays have been described [32, 33].  
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Reference cytokines, such as those used to calibrate ELISA assays, are available in some 
instances in the form of certified (international) RM. However, while a reference cytokine 
can serve to define standard curves and therefore a link to a known concentration of that 
cytokine for an assay such as an ELISA, the reference cytokine is not a RM for the 
biological assay that results in cytokine release.   
 
While not a material standard, approaches that create product ‘signatures’ from complex 
data sets and applied algorithms might have application in demonstrating comparability. 
Examples of such an approach that has been developed to assess (undifferentiated) iPSC 
populations by gene expression analysis include the hPSC Scorecard and PluriTest, either 
by genome-wide microarray (PluriTest [34]) or PCR analysis of a set of selected genes 
(Scorecard [35]), establishing a typical gene expression profile. Users analyze their 
samples via the same method (array or PCR) and compare their samples to the 
established standard generated, in this case, from previous product batches. Such a 
comparison informs users as to how similar their sample profile is to the expected profile. 
This approach might be suitable for the assessment of hPSC-derived products, where a 
developer would perform gene array  (or other) analysis using multiple samples from 
different product batches, and then, using a similar approach to the PluriTest, an 
expression signature for the product would be generated with the identification of 
‘acceptable’ levels of variation. This data set could then be used as a ‘virtual’ method RM 
when assessing comparability of future product batches using the same methodology, in 
the context of a specific product. This approach would facilitate a move away from the 
inaccurate use of a limited set of cell surface markers that are typically used to 
characterize and identify cell populations. Clearly this approach would require validation 
and the application of a suitable RM.  
 
Method RM described here will typically display greater stability profiles than product RM 
due to the inherent plasticity of living cells and their responsiveness to the environment 
(Figure 3). Feasibility factors, including the ability to generate sufficient batch sizes, are 
also more amenable for method RM approaches which should, in general, also carry lower 
costs. A rational mix of method RM for different assays within the overall characterization 
process will be required, as will robust product RM.  
 
A final consideration is how data will be made available and managed once 
method/product RM are established. Given that discussion has focussed on development 
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of in-house RM, there may be no requirement for external publication and management of 
data. However, in the interests of eventually establishing consensus RM, rapid 
dissemination of open access and peer-reviewed publications for community wide access 
would be beneficial as a ‘formal’ record and to catalyze multi-stakeholder dialogue. 
Eventually, it may be possible to develop online data repositories managed by experts in 
both research and regulation that will act as a centralised resource in which in-house RM 
standards can be pooled and potentially inform development of consensus RM guidelines. 
 
The approaches outlined here are by no means exhaustive. Innovative thinking is required 
to envisage novel routes to RM that would be appropriate to the unique characteristics of 
hPSC-derived products and cell-based therapies. It is clear that different approaches will 
have varying levels of application, depending upon the specific product and clinical 
application. 
 
Conclusion 
Uncontrolled variability and irreproducibility are key considerations for the translation of 
PSC-derived therapeutics and for the cell therapy field more broadly. Here we have 
outlined the need for RM, discussed the potential challenges faced by hPSC-derived 
products, and identified possible approaches to alleviate consistency and reproducibility 
concerns in the production of hPSC-derived products. A range of cellular and non-cellular 
approaches to product and method RM generation can be envisioned and have been 
described here, including relevant considerations. The ambition behind this work is for the 
research community and tool providers to engage around these requirements and existing 
industry and regulatory models and terminology, so that potential approaches will be 
assessed and incorporated into practice where appropriate, and that novel thinking will 
lead to approaches that more satisfactorily fulfil the needs outlined.  
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Tables 
 
Table 1. Organizations concerned with the generation and/or oversight of reference 
materials. List of major organisations that play a role in the production, guidance and/or 
directives concerning reference materials for small molecule drugs and biologics. 
Organization Region Description Hyperlink 
National Institute for 
Biological Standards and 
Control (NIBSC) 
UK The leading World Health Organisation (WHO) 
International Laboratory for Standards, is responsible 
for >90% of global WHO Standards. 
(http://www.nibsc.org) 
U.S Pharmacopeia 
Convention (USP) 
US The official organization that sets standards and 
generates reference materials implemented by the 
FDA as law in the United States, used globally in 
over 140 countries. 
(http://www.usp.org/about
-usp) 
World Health Organization 
(WHO) 
International Publishes the International Pharmacopoeia (Ph. Int.) 
which aims to harmonize global pharmaceutical 
standards and administers the establishment of 
international reference materials. 
(http://www.who.int/medic
ines/publications/pharmac
opoeia/overview/en/). 
European Directorate for the 
Quality of Medicines & 
Healthcare (EDQM) 
Europe Responsible for the European Pharmacopoeia (Ph. 
Eur.) commission, the evaluation of manufacturer’s 
quality dossiers for certification, and market 
surveillance program. 
(http://www.edqm.eu/en/e
dqm-homepage-628.html) 
Pharmaceutical and Medical 
Device Regulatory Science 
Society of Japan (PMRJ) 
Japan Produces and distributes Japanese Pharmacopoeia 
Reference Standards as prescribed in the Japanese 
Pharmacopoeia (published by Pharmaceuticals and 
Medicial Devices Agency (PMDA). 
http://www.pmrj.jp/hyojun
/html/frm031.php?lang=e 
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Table 2. Potential approaches to generating reference materials for PSC-derived 
products.  
In-house reference material (RM) for hPSC-derived products will enable the analysis and 
qualification of consistency and promote reproducibility. Product RM are used to ensure 
that a product batch is representative of an intended product and to identify process drift. 
Method RM validate data derived from specific assays, define assay acceptance criteria 
and are a tool to detect method drift.  
 
RM 
category 
RM 
description 
Type Explanation 
Product Primary/ 
secondary 
Cellular Generated as per product. Primary and secondary 
RM. Secondary RM is used as the working 
material which, when depleted is replace with 
product from a new batch and qualified against the 
primary RM.  
Product Pooled  Cellular Generated as per product. RM are produced from 
a pooled bank of cells, a potential benefit is that 
variability is averaged across the population. 
Product/ 
Method 
Biological 
equivalent 
Cellular For a limited number of cell types that can be 
harvested from donors non-invasively e.g. from 
blood, biological equivalent cell populations can 
be used as a RM e.g. expression of CD4 levels on 
peripheral blood T cells and on PSC-derived T 
cells.  
Method Cell lines Cellular Cells lines may have application in a number of 
characterization assays. 
Method Non-cellular Non-cellular Samples such as fixed cells for cell surface 
marker staining, DNA samples for sequencing or 
genotyping and RNA for expression profiling. 
Not a 
physical 
RM 
 
‘Virtual’  Non-cellular Use of transcriptome, proteome, phosphoproteome, or epigenetic mapping to 
generate a complex data set that when 
computational algorithms are applied identifies a 
product ‘signature’ e.g. concept from PluriTest, 
PSC scorecard (Mueller et al., 2011, Bock et al., 
2011). 
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Figure 1. Overview of standards.  
Standards are either written, such as guidance, standard operating procedures (SOPs) 
and pharmacopoeia, or physical (material). Physical (material) standards in turn are 
typically either generated and used as part of an certified (consensus/international) effort 
or developed in-house (local). In-house RM are the focus of the discussion here, both 
product RM and method RM.  
 
 
 
Figure 2. Reference materials are required to demonstrate product comparability 
over time (product RM) and to validate assay results (method RM). 
Product and method RM have multiple applications, two of which are depicted a) Product 
RM are required to demonstrate that product drift does not occur and that a particular 
batch is representative of the pre-clinical or pivotal trial data demonstrating identity, purity, 
safety and potentially mechanism of action/potency. RM generated with Batch B will be 
retained to use as a comparator with Batch D. b) Method RM are needed to validate assay 
results alongside the product sample.  
 
 
Figure 3. Assessing the suitability of alternative reference materials (RM) 
approaches.  Alternative routes to generating product and method RM include cellular 
(PSC-derived; primary/secondary and pooling, non-PSC-derived; cell lines and biological 
equivalent cells) as well as non-cellular approaches. A third approach, while not a physical 
RM is to use large data sets e.g. gene array, generated for a specific product that can then 
be stored as a ‘virtual’ signature to facilitate comparability. When alternative RM are 
assessed for characteristics of suitable reference materials it is clear that biological 
relevance correlates inversely with many desirable criteria such as stability, cost, feasibility 
and potential for global comparisons. (blue= desirable/positive features e.g. high biological 
relevance, low cost; grey= neutral feature e.g. limited biological relevance, mid-range cost; 
red= undesirable/negative features e.g. low biological relevance, high cost).  
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Figure 1 Overview of standards 
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Figure. 2 Reference materials are required to demonstrate product comparability 
over time (product RM) and to validate assay results (method RM). 
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Figure 3. Assessing the suitability of alternative reference materials (RM) 
approaches.   
 
